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Short Communication
Therapy with high dose recombinant alpha 2 interferon
(IFN-o2) produces a depression in natural killer cell
cytotoxicity
B. Tank', R.L. Marquet2, W. Weimar3 and D.L. Westbroek' 2
'Laboratoryfor Experimental Surgery and 2Departments ofSurgery and 3Internal Medicine, Erasmus
University, P.O. Box 1738, 3000 DR Rotterdam, The Netherlands
Interferons (IFNs) possess numerous biological
activities. In addition to their antiviral activity,
interferons are known to have antiproliferative and
immunomodulating properties (Gresser et al., 1979).
One of the most thoroughly investigated properties
of interferons is their ability to modulate natural
killer (NK) cell activity (Einhorn et al., 1978;
Skurkovich et al., 1978; Herberman et al., 1979;
Maluish et al., 1983). Augmentation of NK cell
activity has been reported in a number of studies.
Einhorn et al. (1980) reported an increase in the
NK cell activity 12 to 24h after the first injection of
three million units of natural interferon alpha (IFN-
oc) given daily to 43 patients. In some of these
patients, an increase in the NK cell activity was
preceded by a reduction. Subsequent treatment
maintained an elevated level for up to 9 months.
Highly significant and consistant increase in the
NK cell activity after a single or multiple injection
of three million units of IFN-a2 to patients with
low or medium pretreatment levels of NK cell
activity were reported by Lotzova et al., (1982). No
change was observed in patients with high
pretreatment NK cell activity in these studies. A
significant elevation of NK cell activity 12-24h
after administration of low dose natural IFN-cx was
also observed by Huddlestone et al., (1979). In their
study, the NK cell activity declined rapidly after
18h, but remained higher than the pretreatment
levels.
In this communication, the effect(s) of high dose
IFN-oc2 therapy on the NK cell activity in 10
patients with disseminated colorectal carcinoma are
reported.
Six female and four male patients aged 49-77
years (mean 63 years) with histologically confirmed
resected colorectal carcinoma (Dukes B stage) who
had entered a phase II trial were tested.
The primary tumour had been resected between 2
and 27 months (mean 10 months) before entry. No
radio-, chemo-, or immunotherapy had been given
prior to IFN-a2 therapy. Patients were treated intra
muscularly either chronically (twice a week) or
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cyclically (in 3 periods of 8 consecutive days) with
160 million units of IFN-a2m2month-' during a
period of 3 months. The IFN-a2 was prepared and
purified as described previously (Staehelin et al.,
1981) and was provided by Hoffman-La Roche,
Basel, Switzerland. A therapeutic effect of IFN-a2
was observed only in one chronically treated
patient. This patient showed a near total regression
of a 12cm liver metastasis. Detailed clinical results
of this trial will be published elsewhere (A.M.
Eggermont, manuscript in preparation).
NK cell activity was sequentially evaluated in 8
chronically and 2 cyclically treated patients. Levels
of NK cell activity were determined on Day 0, 2, 7,
28, 56 and 77 after the start of IFN-a2 therapy.
Samples of blood from each patient were collected
in heparinized 10ml tubes. Mononuclear cells were
separated on a Ficoll-hypaque gradient and were
used in standard 3h 5"Cr-release NK cytotoxicity
assay (Ortaldo et al., 1977). The target cell was
K562 and the cells were used at effector to target
ratios of 40:1, 20:1, 10:1 and 5:1. All assays were
performed in triplicate in a total volume of 0.2ml
RPMI 1640 containing 10% foetal calf serum (FCS).
To determine the ability of patient's cells to
respond to IFN-a2 in vitro, five million effector cells
were incubated at 37°C with 1 x 104 units of IFN-
a2. After 1 h, the cells were washed twice, counted
and diluted to the appropriate concentration to be
used as effectors in the cytotoxic assay. To harvest
the assay, the plates were centrifuged and the
supernatants were removed using the Titertek
automatic harvesting system (Skatron, Norway) and
counted in a LKB gamma counter. The percentage
specific lysis in all experiments was calculated as
follows:
% specific lysis=
mean experimental release
-mean spontaneous release
mean maximum release
-mean spontaneous release
x 100.
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The maximum release was calculated by adding
10% Cetavlon (ICI, U.K.) to an aliquot of target
cells. Spontaneous release was defined as the 5tCr
released from target cells incubated with medium
alone; this value was usually 6-10% of the
maximum.
The studies presented here show that in both
chronically (Figure 1, Table I) and cyclically (Figure
2, Table II), treated patients there was a significant
(2-3 fold) augmentation in the NK cell activity on
the second day after IFN-a2 therapy. This
augmentation was 'short-lived' since the NK cell
activity had tapered off when determined on Day 7.
In the chronically treated patients, there was a
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further depression in the NK cell activity during the
course of therapy. On the other hand, the NK cell
activity in the cyclically treated patients was
augmented on the second day after therapy in each
of the three cycles. In each cycle, this elevated
activity then tapered oft and was identical to its
initial level at the beginning of each cycle.
Simultaneous assays performed at the same time
intervals with in vitro IFN-a2 pretreated
lymphocytes showed that the NK cell activity was
significantly boostable only on day 0 in the
chronically treated patients and on Day 0 of each
of the 3 treatment cycles in the cyclically treated
patients. This indicates that in vivo administration
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Figure 1 A typical NK cell cytotoxicity profile at effector to target ratio of 40:1 of patients treated
c/Ironically (twice weekly) with IFN-a2. (0) No effector cell pretreatment. (0) IFN-a2 pretreated effectors.
Table I Mean NK cell activity at effector to target ratio of 40: 1 of patients treated chronically
(twice weekly) with IFN-ac2.
DayO Day 2 Day 7 Day 14 Day 28 Day 56 Day 77
No effector cell pretreatment
IFN-a2 pretreated effectors
43+19 91+ 4 36+10 34+ 6 19+12 24+18 26+17
53+ 9 62+10 42+12 35+ 3 25+12 31+19 29+17
The values of day 2 are significantly different (P<0.05).THERAPY WITH HIGH DOSE RECOMBINANT ALPHA 2 INTERFERON 229
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Figure 2 A typical NK cytotoxicity profile at effector to target ratio of 40:1 of patients treated cyclically (3
cycles of 8 consecutive days) with IFN-a2. (0). No effector cell pretreatment. (a) IFN-a2 pretreated effectors.
Table II Mean NK cell activity at effector to target ratio of 40:1 of patients treated cyclically (3 cycles of 8 consecutive
days) with IFN-a2.
Ist cycle 2nd cycle 3rd cycle
Day 0 Day 2 Day 7 Day 29 Day 31 Day 35 Day 56 Day 58 Day 65
No effector cell pretreatment 35+ 9 80+ 11 47+ 1 25+ 5 43+ 3 40+ 1 30+ 0 50+ 9 40+ 6
IFN-a2 pretreated effectors 42+ 9 47+ 1 50+ 0 35+ 5 38+ 1 44+ 1 43+ 2 32+ 2 43+ 4
of high doses of IFN-a2 apparently leads to the
maximum attainable NK cell activity which cannot
be stimulated further by in vitro incubation with
IFN-a2. The inhibition of NK cell activity using in
vitro IFN-a2 pretreated effectors on Day 2 in both
chronically and cyclically treated patients may be
the result of a direct cytostatic effect of IFN-a2 on
in vivo activated NK cells. This effect disappears on
continued administration of IFN-a2. It is possible
that the observed inhibition on Day 2 represents
the forthcoming in vivo depression of NK cell
activity. At present there is no satisfactory
explanation to our current observations that high
dose IFN-cx2 therapy leads to a temporary elevation
and subsequent depression of NK cell activity. Two
possible interacting mechanisms may be involved.
There are (a) a direct activation of the intrinsic lysis
capacity of NK cells and (b) stimulation or
recruitment of an initially non-cytotoxic NK cell
precursor population. Oehler et al. (1978) and
Saksela et al. (1979) have suggested that interferon
influences the differentiation of active NK cells from
inactive precursors. If this is so, then the failure of
chronic administration of IFN-a2 in high doses to
maintain a sustained optimal NK cell activity could
be explained by the 'exhaustion' of the precursor
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NK cell pool. In the cyclically treated patients this
pool can be replenished during the 20 days interval
between each cycle when no therapy is given.
Our current results are in agreement with those
reported by Maluish et al. (1983) who also observed
that high dose IFN-a2 therapy results in a
depression of NK cell activity in 30% of their
patients. The most severe depression was observed
in patients where a high dose-frequent IFN-a2
administration schedule was used. In contrast, the
results presented here show that irrespective of
mode of treatment (chronic or cyclic), there was a
'short-lived' augmentation in the NK cell activity
after IFN-a2 treatment.
Since NK cells have been implicated to have
antitumour effects even against primary tumours
(Serrate et al., 1982), it would be preferable to
induce a sustained augmentation of NK cell activity
with interferon. In order to achieve this, our current
results would argue for a cyclic low dose IFN-a2
administration schedule.
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